3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
French venture capital firm Sofinnova Partners has announced the closing of a $200 million fund, spearheaded by partners Edward Kliphuis and Simon Turner. 27 October 2023
Swiss pharma giant Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO). 27 October 2023
The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance, recommending the use of Cosentyx (secukinumab) as a treatment option for adults in England and Wales with active moderate to severe hidradenitis suppurativa (HS). 27 October 2023
Gene editing company Verve Therapeutics has been cleared by the US regulator to go ahead with what will be the first in-human base editing study in the country, 26 October 2023
Eisai and Biogen have announced the presentation of new data for their Alzheimer’s drug Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use. 26 October 2023
Privately-held Italian drugmaker Dompé has announced the appointment of Shannon Sullivan as is chief commercial officer (CCO), with immediate effect. 26 October 2023
Independent data monitors have recommended that French microbiome specialist MaaT Pharma continues its Phase III ARES study without modification. 26 October 2023
UK-based Revolo Biotherapeutics, which is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, has announced top-line data from its allergen challenge mapping study. 25 October 2023
The US Centers for Disease Control and Prevention (CDC) is issuing an alert to provide options for clinicians to protect infants from respiratory syncytial virus (RSV) in the context of a limited supply of nirsevimab. 25 October 2023
Fibrocor Therapeutics, a privately-held Canadian developer of therapeutics to treat fibrosis, has named William Newsome III as president and chief executive and Piet Wigerinck as chief scientific advisor.
William Newsome III was one of the co-founders of Fibrocor when he was with German drug discovery firm Evotec (ETR: EVT) and he has remained closely involved with the company as a non-executive director since 2018. 25 October 2023
Boston, USA-based biotech Elektrofi has entered a multi-target research collaboration and license agreement with US pharma major Eli Lilly to develop next-generation medicines that can be delivered subcutaneously. 25 October 2023
Norway’s clinical-stage biopharmaceutical company Nykode Therapeutics today announced that its private placement has been successfully placed, raising around 505 million Norwegian kroner (~$45 million) in gross proceeds through the allocation of 29,549,400 new shares at a subscription price of 17.10 kroner per share. 25 October 2023
At the annual meeting of the American College of Gastroenterology (ACG), Johnson & Johnson has presented data from the Phase III QUASAR trial. 25 October 2023
American critical care specialist Citius Pharma is to list its oncology subsidiary on the Nasdaq exchange, via merger with a special purpose acquisition company (SPAC). 25 October 2023
Shares of Sino-American biotech LianBio shot up 120% to $3.06 in early US trading today, on the news of an agreement with US pharm major Bristol Myers Squibb. 24 October 2023
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish. In this episode of the podcast, we chat with the company’s CCO, George McMillan. 24 October 2023
San Francisco, USA-based biotech start-up Aiolos Bio has today emerged out of stealth, backed by an oversubscribed $245 million Series A investment. 24 October 2023
Germany’s BioNTech has presented positive Phase I/II on its CAR-T cell therapy candidate BNT211 in advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2023. 24 October 2023
At the 2023 annual congress of the European Society of Medical Oncology (ESMO), Johnson & Johnson has presented important new data for Rybrevant (amivantamab-vmjw). 24 October 2023
Chinese drugmaker Sichuan Kelun Pharmaceutical on Monday revealed that Merck & Co was abandoning the joint development of two candidate cancer drugs which have yet to start clinical trials. 24 October 2023
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.